Ambrx, Inc.

Based in California, US, founded in 2003, Ambrx, Inc. develops engineered precision biologics to treat a broad range of diseases and disorders. Feng Tian is the current CEO of the company. In November 2020, Ambrx, Inc.

raised USD 200 million in venture funding from Fidelity Investments, BlackRock, Cormorant Asset Management, Invus Group, Adage Capital Management, and Suvretta Capital Management. The company has 70 employees as of June 2021. In June 2021, Ambrx, Inc. raised USD 126 million in IPO, selling 7 million shares on NYSE.

It trades on NYSE under the ticker symbol AMAM. Ambrx is developing a new class of engineered precision biologics (EPBs) that allow synthetic amino acids (SAAs) to be incorporated into proteins within live cells. Among the products in its pipeline are ARX788, ARX517, and ARX305. ARX788 is an anti-HER2 ADC currently being studied broadly in breast cancer, gastric/GEJ cancer, and other solid tumor clinical trials.

ARX517 targets the prostate-specific membrane antigen (PSMA) expressed on prostate cancer cells. ARX305 targets CD70 on cancer cells. CD70 is overexpressed in a broad range of solid and hematologic tumors such as renal cell carcinoma (RCC), nasopharyngeal cancers, multiple myeloma, non-Hodgkin’s lymphoma, and acute myeloid leukemia (AML). The company's total revenue in 2020 was USD 13,671 which was an increase from that of 2019.

In 2019 the total revenue generated was USD 10,311. The company plans to use the funds raised in venture funding to advance the clinical and preclinical pipeline of precision biologics.